| Title: | Individualized prevention of proton pump inhibitor related adverse events by risk stratification |
| Journal: | Nature Communications |
| Published: | 27 Apr 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38678022/ |
| DOI: | https://doi.org/10.1038/s41467-024-48007-8 |
| URL: | http://dx.doi.org/10.1038/s41467-024-48007-8 |
Publication 9796
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public.</p>
15 Authors
- Bin Xia
- Qiangsheng He
- Fang Gao Smith
- V. Georgios Gkoutos
- Krishnarajah Nirantharakumar
- Zi Chong Kuo
- Danni Wang
- Qi Feng
- Eddie C. Cheung
- Lunzhi Dai
- Junjie Huang
- Yuanyuan Yu
- Wenbo Meng
- Xiwen Qin
- Jinqiu Yuan
1 Application
| Application ID | Title |
|---|---|
| 51671 | Metabolism syndrome and risk of cancer |
Enabling scientific discoveries that improve human health